SuperworthPACS profit margin PACS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.
- Net margin, 12 months
- 4.8%
- Operating margin, 12 months
- 7.4%
- Net margin on a year earlier
- +2.1 pts
- Peer median
- 7.7%
Over the twelve months to Jun 30, 2026, PACS kept 4.8% of its revenue as net profit, with an operating margin of 7.4% and a gross margin of 16.6%.
The median for 10 hospital and care facility stocks of a similar size is 7.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 3.6% | 5.9% | 14.8% |
| FY2024 | 1.4% | 3.0% | 12.4% |
| FY2023 | 3.6% | 6.7% | 14.4% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 4.8% | +2.1 pts | 7.4% | |
| Q1 FY26 | 4.5% | +3.4 pts | 7.0% | |
| Q4 FY25 | 3.6% | +2.3 pts | 5.9% | |
| Q3 FY25 | 3.3% | +1.9 pts | 5.6% | |
| Q2 FY25 | 2.7% | +1.1 pts | 4.6% | |
| Q1 FY25 | 1.1% | −2.2 pts | 2.4% | |
| Q4 FY24 | 1.4% | −2.3 pts | 3.0% | |
| Q3 FY24 | 1.4% | n/a | 3.0% | |
| Q2 FY24 | 1.6% | n/a | 3.6% | |
| Q1 FY24 | 3.3% | n/a | 6.4% | |
| Q4 FY23 | 3.6% | n/a | 6.7% | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Medical - Care Facilities nearest PACS' size, closest first, today.
| Company | Profit margin |
|---|---|
| PACSPACS | 4.8% |
| CHEChemed | 10.6% |
| ENSGEnsign | 6.9% |
| UHSUniversal Health Services | 8.4% |
| SHCSotera Health | 13.4% |
| CONConcentra Group Holdings Parent | 8.7% |
| LFSTLifeStance Health | 3.2% |
| DVADavita | 6.0% |
| BTSGBrightSpring Health Services | 2.5% |
| OPCHOption Care Health | 3.7% |
| EHCEncompass Health | 10.0% |
| Peer median | 7.7% |
Where PACS ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on PACS
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.